Failed to read the fine print – lost his life’s work

A celebrated CEO and co-founder of a pioneering lab company one moment – the next, fired, kicked out and written out of the company’s history. This is the story...

Krönika: Can regulators keep up with innovation?

New technology has increased the understanding of disease mechanisms and enabled approval of products targeting small but specific patient populations; sometime...

Anna Törner: Kalashnikovs in a new guise

Thanks to resisting European regulatory authorities, Europe has been spared the opioid epidemic. In the 1960s, the situation was the opposite as the American ph...

The route to vaccines for everyone: “We did not just sit around and wait”

The pandemic was in full swing, and no one knew when or even if a vaccine would come. At that point, the Swedish Minister of Social Affairs called with a propos...

Handeln med Creatives aktie återupptas

Aktien stannar dock kvar på Aktietorgets observationslista.

Creative Antibiotics handelsstoppat på börsen

Information från bolaget väntas imorgon tisdag.

Anna Törner: To kill your darlings

Hopes were high when Anna Törner and her colleague started a study on a dietary supplement that seemed unbelievably good. “Enthusiastically, we dreamed of excit...

The first drugs to slow down Alzheimer’s – but what does it mean for patients?

New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the ri...

Creative antibiotics breddar portföljen

Tecknar nytt samarbetsavtal. Har tredubblat antalet projekt på ett år.

Creative-substans effektiv mot lunginflammation

Framsteg för ny antibiotikatyp. Visar positiva resultat i djurstudier med ny läkemedelskandidat.

Chefen för MHRA lämnar

Ian Hudson, chef för den nationella brittiska läkemedelsmyndigheten meddelar att han lämnar posten i september nästa år.

Creative antibiotics rensar i portföljen

Avbryter utvecklingssamarbete med norska Qotics.

Björn Arvidsson: Let's build on the positive momentum

Progress needs narratives and heroes, and more than ever, going into the new year feels like an opportunity for a fresh start.

They’re all doing it – buying drug research

It is not easy to navigate the complex infrastructure for drug development in Sweden, where various contract players exist alongside the pharmaceutical companies.

Creatives substanser möjlig bot av EHEC

Visar positiv effekt mot E. coli-bakterier. Nu ska substanserna testas mot infektionssjukdomen EHEC.

Efter positiva resultat för Valneva: ”Ansökan till EMA skickas så snart som möjligt”

Efter att ha stoppats av Storbritannien ser det nu ljusare ut för Valnevas covid-19-vaccinkandidat sedan positiva fas III-resultat presenterats. Nu väntar ansök...

Svenska bolag på infektionsmässa i USA

Flera svenskar är på plats på ICAAC som hålls just nu i San Fransisco, USA. Biotech Sweden har pratat med Björn Ursing från Västerbotten Investment Agency.

Column: Repurposing as a golden ticket to approval

"Hopefully, in the end, patients will be winners by receiving on-label treatments for which benefit-risk has been properly assessed." In a column Marie Gårdmark...

Hemarbete ökar risken för nätfiske i läkemedelsföretag

Allt fler hackerförsök inom läkemedelsbranschen riktar sig mot anställdas mobiltelefoner.

Lucka 4 - vem finns här?

Bakom den fjärde luckan önskar sig vd:n att föreläsaren och succéförfattaren ska slå en signal...

Marie Gårdmark: Big data evidence generation drives change in the EU regulatory system

Rapid developments in technology have led to the possibility for the generation and analysis of vast volumes of data. Will the availability of big data lead to ...

Drug development creates new challenges for regulators

EMA till Amsterdam

Det stod klart efter kvällens omröstning i Allmänna rådet i Bryssel. Sverige åkte ut redan i första röstningsomgången.

Sweden and Denmark – this is how they choose their strategies

Scandinavia’s two major powers in pharmaceutical research have developed strategies for growth in life science, and both countries aim to become world leaders.